Sanofi and REVOLUTION Medicines launch global partnership
Sanofi and REVOLUTION Medicines announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cellular enzyme SHP2, for patients with non-small lung cancer and other types of cancer carrying certain mutations. July 18, 2018